KALV News & Events

Chiesi Group announced the completion of its acquisition of KalVista Pharmaceuticals. KalVista is now part of Chiesi Group and will contribute to the growth of the Rare Diseases business unit, focused on research, development and commercialization of therapies for rare and ultra-rare conditions. With the completion of the transaction, Chiesi assumed ownership of EKTERLY, an oral, on-demand treatment for hereditary angioedema attacks in adults and adolescents aged 12 years and older. EKTERLY is already approved in the United States, United Kingdom, European Union, Japan and other regions, with ongoing studies exploring its use for treating HAE attacks in children aged 2 to 11, and multiple regulatory applications under review in key global markets. On June 11, Chiesi completed its tender offer for all outstanding shares of KalVista common stock for $27.00 per share in cash and accepted for payment all shares validly tendered and not validly withdrawn as of the expiration time of the tender offer, which shares represented approximately 77.8% of KalVista's outstanding shares. Following completion of the offer, Chiesi completed its acquisition of KalVista through a merger of a wholly owned subsidiary of Chiesi with and into KalVista, in connection with which the outstanding shares of KalVista common stock were cancelled and converted into the right to receive the same $27.00 per share in cash. As a result of the merger, KalVista became a wholly owned subsidiary of Chiesi and KalVista's common stock ceased trading on the Nasdaq Global Market.

KalVista Pharmaceuticals announced new data highlighting the burden of injectable on-demand treatment in children aged 2-11 with hereditary angioedema presented at ISPOR 2026 and the Eastern Allergy Conference. On-Demand Treatments for Hereditary Angioedema and Healthcare Resource Utilization in Pediatric Patients: A US Claims Database Analysis: Real-world claims data showed that while about two thirds of children aged 2-11 were prescribed IV pdC1INH-the only FDA-approved on-demand HAE treatment for this population-the majority of treatments utilized were off-label, suggesting families and providers may be seeking less invasive treatment options. Although the mean on-demand dosing rate was 0.43 per patient per month, the rate for pdC1INH was far less than that of icatibant. Burden of Injectable On-Demand Treatment for Hereditary Angioedema Attacks in Children: A caregiver survey found that nearly half of children did not receive on-demand treatment for their most recent HAE attack. Among children who did treat their last attack, 93.7% experienced anxiety about using injectable on-demand treatment, with 68.8% reporting extreme anxiety. Caregiver Burden Associated with Injectable On-Demand Treatment of Hereditary Angioedema Attacks in Children: The same caregiver survey found that during their child's last HAE attack, 43% occurred outside the home and 37% occurred while they were not with their child. 63% of caregivers had difficulty administering treatment and 31% took their child to a hospital or emergency center for treatment.

Stifel analyst Paul Matteis downgraded KalVista to Hold from Buy after the company entered into a merger agreement to be acquired by Chiesi Group at a price of $27 per share in cash.

H.C. Wainwright analyst Andrew Fein downgraded KalVista to Neutral from Buy with a price target of $27, down from $37, after the company entered into a merger agreement to be acquired by Chiesi Group at a price of $27 per share in cash at closing. The firm does not expect an additional bidder to emerge.